Cagrilintide vs retatrutide compares two investigational weight loss drugs. Learn how their mechanisms, trial results, and side effects differ.
Cagrilintide and retatrutide are both investigational medications being studied for weight loss, but they work in different ways. Cagrilintide is an amylin analog, while retatrutide is a triple agonist that targets GIP, GLP-1, and glucagon receptors. Neither drug is FDA-approved for human use, and no head-to-head trials have compared them directly. The comparison is the same whether you search for cagrilintide vs retatrutide or retatrutide vs cagrilintide.
What Is Cagrilintide?
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. It mimics the hormone amylin, which helps regulate satiety and slows gastric emptying. Researchers have studied cagrilintide both alone and in combination with semaglutide, a combination known as CagriSema.
Cagrilintide is a modified version of human amylin. The modification makes it last much longer in the body, allowing for once-weekly dosing. It is being evaluated in the REDEFINE phase 3 clinical trial program.
Mechanism of Action
Cagrilintide binds to amylin and calcitonin receptors in the brain. This action reduces appetite and food intake. By slowing how quickly the stomach empties, cagrilintide also helps people feel full longer.
Clinical Trial Results for Cagrilintide
In phase 2 trials, cagrilintide monotherapy produced up to 10.8% weight loss after 26 weeks. When combined with semaglutide 2.4 mg, the CagriSema combination achieved 15.4% weight loss at 32 weeks. The cagrilintide dosage used in these trials ranged from 0.3 mg to 4.5 mg per week.
Cagrilintide is not FDA-approved for weight loss or any other human use. It remains an investigational drug. Common side effects of cagrilintide in trials included nausea, vomiting, diarrhea, and constipation.
What Is Retatrutide?
Retatrutide is an investigational triple agonist developed by Eli Lilly. It activates three receptors: GIP, GLP-1, and glucagon. This multi-receptor action is designed to reduce appetite, improve insulin sensitivity, and increase energy expenditure.
Retatrutide is being studied in the TRIUMPH phase 3 program. It is a single molecule that binds to all three receptors, which distinguishes it from dual agonists like tirzepatide.
Mechanism of Action
By targeting GLP-1 and GIP, retatrutide reduces hunger and slows digestion. The glucagon component may increase calorie burning. This triple mechanism is thought to be why retatrutide produces greater weight loss than single or dual agonists.
Clinical Trial Results for Retatrutide
In a phase 2 trial, participants taking retatrutide 12 mg weekly lost an average of 24.2% of their body weight after 48 weeks. Lower doses also produced significant weight loss. Retatrutide is not FDA-approved for human use. Retatrutide also improved blood sugar control in people with type 2 diabetes, though weight loss was slightly lower in that group.
Cagrilintide vs Retatrutide: Key Differences
The table below summarizes the main differences between cagrilintide and retatrutide based on published clinical trial data.
| Feature | Cagrilintide | Retatrutide |
|---|---|---|
| Drug class | Amylin analog | Triple agonist (GIP/GLP-1/glucagon) |
| Developer | Novo Nordisk | Eli Lilly |
| Administration | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Phase 2 weight loss | Up to 10.8% alone (26 weeks); 15.4% with semaglutide (32 weeks) | Up to 24.2% (48 weeks, 12 mg) |
| Dose range studied | 0.3 mg to 4.5 mg weekly | 1 mg to 12 mg weekly |
| FDA status | Not approved | Not approved |
| Common side effects | Nausea, vomiting, diarrhea, constipation | Nausea, diarrhea, vomiting, constipation, increased heart rate |
Both drugs are given as weekly subcutaneous injections. Neither is available by prescription. For a broader view of how these drugs fit into the weight-loss landscape, see cagrilintide vs retatrutide vs tirzepatide.
Weight Loss Efficacy: How Do They Stack Up?
Direct comparisons between cagrilintide and retatrutide are not possible because no head-to-head trials have been conducted. The trials also differed in duration, dose, and patient population.
Retatrutide produced greater average weight loss than cagrilintide alone. However, cagrilintide combined with semaglutide narrowed the gap. Cagrilintide alone at 4.5 mg led to about 10.8% weight loss at 26 weeks, while retatrutide 12 mg led to 24.2% at 48 weeks.
It is important to note that these are average results. Individual responses vary widely. Some people may lose more or less weight on either drug.
In addition, the retatrutide trial included people with obesity but without diabetes. The cagrilintide trials included different populations. These differences make cross-trial comparisons imperfect. The highest dose of retatrutide (12 mg) is not necessarily the dose that will be approved. Phase 3 trials are testing different doses.
Side Effects and Safety Profile
Both cagrilintide and retatrutide can cause gastrointestinal side effects. The most common include nausea, vomiting, diarrhea, and constipation. These effects are usually mild to moderate and often improve over time.
Retatrutide has been associated with a small increase in heart rate in some trials. Cagrilintide may cause injection site reactions. Long-term safety data are not yet available for either drug.
Because neither drug is FDA-approved, they should not be used outside of clinical trials. Anyone considering these medications should consult a healthcare professional. Online discussions, such as those found in cagrilintide vs retatrutide reddit threads, are not a substitute for medical advice.
Some participants discontinued treatment because of side effects. The rate of discontinuation was higher with higher doses.
Availability and Legal Status
Neither cagrilintide nor retatrutide is available for prescription in the United States. Both are investigational and can only be accessed through clinical trials. Buying these drugs from unregulated sources is illegal and potentially dangerous.
Some people search for cagrilintide vs retatrutide reddit to find user experiences, but those anecdotes do not reflect clinical evidence. The FDA has not approved either drug for any indication. Clinical trials are the only legal way to access these drugs. Eligibility criteria vary by study.
Which One Is Better for Weight Loss?
Based on current trial data, retatrutide appears to produce greater weight loss than cagrilintide alone. However, cagrilintide combined with semaglutide may be more effective than cagrilintide by itself.
There is no clear winner because no head-to-head study has compared them. Factors such as tolerability, cost, and availability will matter once these drugs are approved, if they are approved.
Some researchers also investigate aod 9604 and retatrutide for fat loss, but AOD 9604 is a different peptide with a distinct mechanism. It is not a substitute for either cagrilintide or retatrutide. Future head-to-head trials could change the picture. Until then, patients and doctors must rely on indirect comparisons.
Related Research on Fat-Loss Peptides
Other peptides are also studied for weight loss. Comparisons such as aod 9604 vs hgh and sermorelin vs aod 9604 focus on different growth hormone pathways. None of these are FDA-approved for weight loss.
Frequently Asked Questions
Is cagrilintide or retatrutide better for weight loss?
Based on phase 2 trials, retatrutide produced greater average weight loss (up to 24.2%) than cagrilintide alone (up to 10.8%). However, no head-to-head trials have compared them directly, so it is not possible to say which is definitively better.
Is cagrilintide FDA-approved?
No, cagrilintide is not FDA-approved for any human use. It is an investigational drug being studied in clinical trials for weight loss and diabetes.
Can I buy cagrilintide or retatrutide online?
No, neither drug is legally available for purchase. They are investigational and can only be accessed through clinical trials. Buying them from online vendors is illegal and unsafe.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.